Infectious Disease

William Schaffner, MD, a veteran infectious disease expert and public health thought leader is concerned that rapidly shifting federal policy could impact future options.

The 9 influenza vaccines available for the upcoming respiratory virus season come from 4 manufacturers in single-dose syringes and vials and multidose vials may still be available.

Family physician Sarah Sams, MD, shares how to improve pediatric vaccine coadministration using pre‑visit planning and staff coordination.

Schaffner describes the mood among his colleagues in infectious disease right now as anxious, perplexed, distressed, and angry. They expect the disruptions and their feelings to continue.

Effective pediatric vaccine conversations require trust and facts. Family physician Sarah Sams, MD, offers tips for addressing concerns without harming patient relationships.

Your daily dose of the clinical news you may have missed.

From EMR reports to targeted nurse visits, Sarah Sams, MD, outlines practical ways PCPs can catch up pediatric vaccinations before school starts.

FDA accepts priority review of gepotidacin for uncomplicated urogenital gonorrhea, with phase 3 data showing non-inferiority to standard injectable therapy.

Board-certified family physician Sarah Sams, MD, urges physicians to actively engage their communities to build vaccine confidence and combat misinformation.

Infectious disease physician Amesh Adalja, MD, explains how PCPs can reframe vaccines as health technology to boost confidence and counter hesitancy.

Since his Senate approval as head of HHS in February, RFK Jr has enacted and/or proposed seismic changes to US vaccine policy that will impact your daily care of patients.

Amesh Adalja, MD, urges physicians to use their trusted position to counter widespread vaccine misinformation and strengthen patient confidence in immunization.

Amesh Adalja, MD, advises physicians turn to specialty societies for evidence-based, reliable recommendations this respiratory virus season.

Amesh Adalja, MD, explains how physicians can rebut social media vaccine claims with concise, referenced facts and patient-centered communication.

Dr Adalja offers evidence-based strategies to address patient concerns about aluminum and thimerosal in vaccines.

Infectious disease expert Amesh Adalja, MD, outlines the biggest vaccine policy shifts of 2025, including changes to COVID-19 and flu vaccine recommendations.

Nirsevimab lowered the risk of RSV-related illness by over 87% and hospitalizations by 98% in a new study.

Vaccination lowered influenza cases by about 33% to 42% in seasonal flu setups with 40% vaccine effectiveness, researchers reported.

Merck has launched phase 3 trials for MK-8527, a promising once-monthly HIV prevention pill, aiming to enhance PrEP options globally.

These new FDA-approved drugs include treatments for migraine, chronic spontaneous urticaria, RSV, and more.

The adult vaccine market is poised for explosive growth, with more than 100 product launches expected over the next 10 years. Are US clinicians ready?

Moderna’s Spikevax receives full FDA approval for use in children at increased risk for COVID-19, expanding protection ahead of the 2025–2026 virus season.

New findings showcase the transformative impact of long-acting injectable therapies for effective HIV treatment and prevention.

A new study found racial disparities in COVID-19 antiviral prescribing, with clinic site, test type, and telehealth use explaining up to half the gap for Black and Latino patients.

Among recipients of high-dose CVXGA, relative vaccine effectiveness was 67.8% against symptomatic COVID infection at a median 7.3 months post-vaccination.